FMR LLC trimmed its position in shares of The Chemours Company (NYSE:CC - Free Report) by 18.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,802,734 shares of the specialty chemicals company's stock after selling 3,339,468 shares during the quarter. FMR LLC owned about 9.91% of Chemours worth $250,166,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in CC. GAMMA Investing LLC lifted its holdings in shares of Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 765 shares during the period. Quadrant Capital Group LLC increased its holdings in Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after acquiring an additional 1,119 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Chemours during the 4th quarter worth about $48,000. KBC Group NV boosted its stake in shares of Chemours by 38.2% in the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after acquiring an additional 1,708 shares during the last quarter. Finally, EMC Capital Management grew its holdings in shares of Chemours by 74.6% during the fourth quarter. EMC Capital Management now owns 9,534 shares of the specialty chemicals company's stock worth $161,000 after buying an additional 4,073 shares in the last quarter. 76.26% of the stock is owned by institutional investors and hedge funds.
Chemours Stock Down 3.4 %
NYSE CC traded down $0.40 on Tuesday, reaching $11.13. The company had a trading volume of 1,744,948 shares, compared to its average volume of 1,822,571. The firm has a 50-day moving average of $14.40 and a 200-day moving average of $17.54. The Chemours Company has a 1 year low of $9.33 and a 1 year high of $29.21. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The firm has a market capitalization of $1.66 billion, a PE ratio of 19.52 and a beta of 1.84.
Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The company had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.37 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. On average, equities research analysts anticipate that The Chemours Company will post 2.03 EPS for the current fiscal year.
Chemours Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 8.99%. The ex-dividend date was Friday, February 28th. Chemours's dividend payout ratio (DPR) is presently 175.44%.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on CC. The Goldman Sachs Group cut their price objective on Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research report on Tuesday, January 7th. Morgan Stanley decreased their price target on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Barclays cut their price target on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 1st. BMO Capital Markets reduced their price objective on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. Finally, Mizuho set a $15.00 price target on Chemours in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $21.56.
Check Out Our Latest Report on Chemours
About Chemours
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Stories
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
